|Bid||7.52 x 1000|
|Ask||7.75 x 900|
|Day's range||7.53 - 7.80|
|52-week range||6.25 - 15.44|
|Beta (5Y monthly)||0.62|
|PE ratio (TTM)||N/A|
|Earnings date||24 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.19|
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
CTMX earnings call for the period ending December 31, 2020.